Macrophage mineralocorticoid receptor signaling plays a key role in aldosterone-independent cardiac fibrosis

Endocrinology

Volumn 153, Issue 7, 2012, Pages 3416-3425

  Bienvenu, Laura A ^a,b   Morgan, James ^a   Rickard, Amanda J ^a,c,d,e   Tesch, Greg H ^c,f   Cranston, Greg A ^a   Fletcher, Elizabeth K ^a   Delbridge, Lea M D ^b   Young, Morag J ^a,c,f  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d INSERM   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f Department of Medicine   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 5; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; MINERALOCORTICOID RECEPTOR; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROTEIN P22; PROTEIN P22PHOX; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; GENE EXPRESSION; HEART MUSCLE FIBROSIS; MACROPHAGE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; VASCULITIS;

ALDOSTERONE; ANGIOTENSIN AMIDE; ANIMALS; FIBROSIS; HEART; HYPERTENSION; MACROPHAGES; MALE; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PHENOTYPE; RECEPTORS, MINERALOCORTICOID; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84862737919     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2011-2098     Document Type: Article

References (46)

1. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J 1999 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709-717 (Pubitemid 29407370)
2. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M 2003 Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309-1321 (Pubitemid 36384098)
3. Funder JW 2005 RALES, EPHESUS and redox. J Steroid Biochem Mol Biol 93:121-125 (Pubitemid 40602484)
4. Young MJ, Lam EY, Rickard AJ 2007 Mineralocorticoid receptor activation and cardiac fibrosis. Clin Sci (Lond) 112:467-475 (Pubitemid 46762007)
5. Ward MR, Kanellakis P, Ramsey D, Funder J, Bobik A 2001 Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 104:467-472 (Pubitemid 32678279)
6. Mihailidou AS, Funder JW 2005 Nongenomic effects of mineralocorticoid receptor activation in the cardiovascular system. Steroids 70:347-351 (Pubitemid 40616031)
7. Rossier MF, Lenglet S, Vetterli L, Python M, Maturana A 2008 Corticosteroids and redox potential modulate spontaneous contractions in isolated rat ventricular cardiomyocytes. Hypertension 52:721-728
8. Lahera V, Salazar J, Salom MG, Romero JC 1992 Deficient production of nitric oxide induces volume-dependent hypertension. J Hypertens (Suppl 10):S173-S177 (Pubitemid 23045184)
9. Baylis C, Mitruka B, Deng A 1992 Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 90:278-281
10. Ribeiro MO, Antunes E, de Nucci G, Lovisolo SM, Zatz R 1992 Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension 20:298-303
11. Arnal JF, Warin L, Michel JB 1992 Determinants of aortic cyclic guanosine monophosphate in hypertension induced by chronic inhibition of nitric oxide synthase. J Clin Invest 90:647-652
12. Moncada S, Higgs A 1993 The L-arginine-nitric oxide pathway. N Engl J Med 329:2002-2012 (Pubitemid 24015045)
13. Tsukamoto O, Minamino T, Sanada S, Okada K, Hirata A, Fujita M, Shintani Y, Yulin L, Asano Y, Takashima S, Yamasaki S, Tomoike H, Hori M, Kitakaze M 2006 The antagonism of aldosterone receptor prevents the development of hypertensive heart failure induced by chronic inhibition of nitric oxide synthesis in rats. Cardiovasc Drugs Ther 20:93-102 (Pubitemid 43876092)
14. Persy VP, Verhulst A, Ysebaert DK, De Greef KE, De Broe ME 2003 Reduced postischemic macrophage infiltration and interstitial fibrosis in osteopontin knockout mice. Kidney Int 63:543-553 (Pubitemid 36126800)
15. Dewald O, Zymek P, Winkelmann K, Koerting A, Ren G, Abou-Khamis T, Michael LH, Rollins BJ, Entman ML, Frangogiannis NG 2005 CCL2/monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res 96:881-889 (Pubitemid 40604972)
16. Rickard AJ, Morgan J, Tesch G, Funder JW, Fuller PJ, Young MJ 2009 Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 54:537-543
17. Clausen BE, Burkhardt C, Reith W, Renkawitz R, Förster I 1999 Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res 8:265-277 (Pubitemid 29523965)
18. Rickard AJ, Funder JW, Fuller PJ, Young MJ 2006 The role of the glucocorticoid receptor in mineralocorticoid/salt-mediated cardiac fibrosis. Endocrinology 147:5901-5906 (Pubitemid 44833507)
19. Rickard AJ, Funder JW, Morgan J, Fuller PJ, Young MJ 2007 Does glucocorticoid receptor blockade exacerbate tissue damage after mineralocorticoid/salt administration? Endocrinology 148:4829-4835 (Pubitemid 47481545)
20. Young M, Head G, Funder J 1995 Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 269:E657-E662
21. Brilla CG, Weber KT 1992 Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 120:893-901 (Pubitemid 23002899)
22. Robert V, Silvestre JS, Charlemagne D, Sabri A, Trouvé P, Wassef M, Swynghedauw B, Delcayre C 1995 Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension 26:971-978
23. Daniels A, van Bilsen M, Goldschmeding R, van der Vusse GJ, van Nieuwenhoven FA 2009 Connective tissue growth factor and cardiac fibrosis. Acta Physiol (Oxf) 195:321-338
24. Ghosh AK, Vaughan DE 2012 PAI-1 in tissue fibrosis. J Cell Physiol 227:493-507
25. Pohlers D, Brenmoehl J, Löffler I, Müller CK, Leipner C, Schultze-Mosgau S, Stallmach A, Kinne RW, Wolf G 2009 TGF-β and fibrosis in different organs-molecular pathway imprints. Biochim Biophys Acta 1792:746-756
26. Leopold JA, Cap A, Scribner AW, Stanton RC, Loscalzo J 2001 Glucose-6-phosphate dehydrogenase deficiency promotes endothelial oxidant stress and decreases endothelial nitric oxide bioavailability. FASEB J 15:1771-1773
27. Usher MG, Duan SZ, Ivaschenko CY, Frieler RA, Berger S, Schütz G, Lumeng CN, Mortensen RM 2010 Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest 120:3350-3364
28. Michel T, Vanhoutte PM 2010 Cellular signaling and NO production. Pflugers Arch 459:807-816
29. Taylor EL, Megson IL, Haslett C, Rossi AG 2003 Nitric oxide: a key regulator of myeloid inflammatory cell apoptosis. Cell Death Differ 10:418-430 (Pubitemid 36626354)
30. Singh A, Sventek P, Larivière R, Thibault G, Schiffrin EL 1996 Inducible nitric oxide synthase in vascular smooth muscle cells from prehypertensive spontaneously hypertensive rats. Am J Hypertens 9:867-877 (Pubitemid 26375949)
31. Coleman JW 2001 Nitric oxide in immunity and inflammation. Int Immunopharmacol 1:1397-1406 (Pubitemid 32622786)
32. Funder JW, Pearce PT, Smith R, Smith AI 1988 Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242:583-585 (Pubitemid 18263202)
33. Edwards CR, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS, de Kloet ER, Monder C 1988 Localisation of 11 β-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor. Lancet 2:986-989
34. Monder C 1993 The forms and functions of 11 β-hydroxysteroid dehydrogenase. J Steroid Biochem Mol Biol 45:161-165
35. Joëls M, Karst H, DeRijk R, de Kloet ER 2008 The coming out of the brain mineralocorticoid receptor. Trends Neurosci 31:1-7
36. Funder JW 2009 Reconsidering the roles of the mineralocorticoid receptor. Hypertension 53:286-290
37. Wilson P, Morgan J, Funder JW, Fuller PJ, Young MJ 2009 Mediators of mineralocorticoid receptor-induced profibrotic inflammatory responses in the heart. Clin Sci (Lond) 116:731-739
38. Keidar S, Hayek T, Kaplan M, Pavlotzky E, Hamoud S, Coleman R, Aviram M 2003 Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 41:955-963 (Pubitemid 36706146)
39. Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S, Aviram M 2004 Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin- converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 109:2213-2220 (Pubitemid 38625399)
40. Rickard AJ, Young MJ 2009 Corticosteroid receptors, macrophages and cardiovascular disease. J Mol Endocrinol 42:449-459
41. Woollard KJ, Geissmann F 2010 Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol 7:77-86
42. Russo G, Leopold JA, Loscalzo J 2002 Vasoactive substances: nitric oxide and endothelial dysfunction in atherosclerosis. Vascul Pharmacol 38:259-269 (Pubitemid 36398259)
43. Young M, Fullerton M, Dilley R, Funder J 1994 Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 93:2578-2583 (Pubitemid 24177174)
44. Young MJ, Funder JW 1996 Mineralocorticoids, salt, hypertension: effects on the heart. Steroids 61:233-235 (Pubitemid 26144428)
45. Lother A, Berger S, Gilsbach R, Rösner S, Ecke A, Barreto F, Bauersachs J, Schütz G, Hein L 2011 Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function. Hypertension 57:746-754
46. Fraccarollo D, Berger S, Galuppo P, Kneitz S, Hein L, Schütz G, Frantz S, Ertl G, Bauersachs J 2011 Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation 123:400-408